Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide maintenance after first-line chemotherapy in malignant mesothelioma
ISRCTN13632914Phase 3Completed
- Sponsor
- NVALT
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mesothelioma comparing Thalidomide plus best supportive care with Observation plus best supportive care (2 arms). Primary endpoint: Time to recurrence. Started Sep 2004; status: completed.
02
Drugs
thalidomide
03
Conditions
mesothelioma
Beyond the preview
Go deeper on ISRCTN13632914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13632914.